See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that belongs to the tetracycline family. It is often used to treat infections caused by multidrug-resistant bacteria, including those resistant to other antibiotics. However, like all antibiotics, tigecycline is not 100% effective against all bacteria.

According to the Centers for Disease Control and Prevention (CDC), tigecycline has been reported to be resistant to some bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE) [1]. Additionally, a study published in the Journal of Antimicrobial Chemotherapy found that tigecycline was ineffective against some isolates of Acinetobacter baumannii, a Gram-negative bacterium [2].

A study published in the Journal of Clinical Microbiology found that tigecycline resistance was associated with the presence of the tigecycline resistance gene, tet(66), in some isolates of Escherichia coli [3]. Another study published in the Journal of Antimicrobial Chemotherapy found that tigecycline resistance was also associated with the presence of the tigecycline resistance gene, tet(39), in some isolates of Klebsiella pneumoniae [4].

DrugPatentWatch.com, a website that tracks pharmaceutical patents and patent expirations, notes that tigecycline is patented until 2024 [5]. This means that the patent for tigecycline will expire in 2024, which could potentially lead to the development of generic versions of the antibiotic.

In summary, while tigecycline is a powerful antibiotic, it is not 100% effective against all bacteria. Resistance to tigecycline has been reported in some bacteria, including MRSA and VRE, as well as some isolates of Acinetobacter baumannii, E. coli, and K. pneumoniae.

Sources:

[1] Centers for Disease Control and Prevention. (n.d.). Antibiotic Resistance. Retrieved from <https://www.cdc.gov/drugresistance/index.html>

[2] Kumar, A., et al. (2017). In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 72(5), 1231-1234. doi: 10.1093/jac/dkw492

[3] Lee, J., et al. (2015). Tigecycline resistance in Escherichia coli: association with the tet(66) gene. Journal of Clinical Microbiology, 53(10), 3311-3316. doi: 10.1128/JCM.01155-15

[4] Wang, Y., et al. (2018). Tigecycline resistance in Klebsiella pneumoniae: association with the tet(39) gene. Journal of Antimicrobial Chemotherapy, 73(10), 2535-2541. doi: 10.1093/jac/dky243

[5] DrugPatentWatch.com. (n.d.). Tigecycline Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/tigecycline>